CINECA IRIS Institutional Research Information System

FERRARO, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.553
AS - Asia 2.089
EU - Europa 1.659
SA - Sud America 344
AF - Africa 184
Continente sconosciuto - Info sul continente non disponibili 112
OC - Oceania 24
Totale 8.965
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.470
SG - Singapore 685
IT - Italia 474
CN - Cina 437
SE - Svezia 303
HK - Hong Kong 280
BR - Brasile 267
VN - Vietnam 208
GB - Regno Unito 173
DE - Germania 168
IN - India 153
FR - Francia 120
FI - Finlandia 88
JP - Giappone 82
CI - Costa d'Avorio 79
BG - Bulgaria 78
NL - Olanda 53
TR - Turchia 51
CA - Canada 42
RU - Federazione Russa 41
SN - Senegal 37
PL - Polonia 29
ID - Indonesia 28
AR - Argentina 24
AU - Australia 23
KR - Corea 23
NG - Nigeria 23
IQ - Iraq 20
AT - Austria 19
BD - Bangladesh 19
ES - Italia 19
MX - Messico 19
EC - Ecuador 15
SA - Arabia Saudita 14
PT - Portogallo 13
ZA - Sudafrica 12
IR - Iran 11
UZ - Uzbekistan 11
LT - Lituania 10
CZ - Repubblica Ceca 9
PE - Perù 9
UA - Ucraina 9
VE - Venezuela 9
EG - Egitto 8
IE - Irlanda 8
MA - Marocco 8
PK - Pakistan 8
CO - Colombia 7
JO - Giordania 7
AE - Emirati Arabi Uniti 6
BE - Belgio 6
CL - Cile 6
JM - Giamaica 6
PH - Filippine 6
RO - Romania 6
CR - Costa Rica 5
GR - Grecia 5
KZ - Kazakistan 5
PY - Paraguay 5
RS - Serbia 5
XK - ???statistics.table.value.countryCode.XK??? 5
AZ - Azerbaigian 4
DZ - Algeria 4
NP - Nepal 4
TT - Trinidad e Tobago 4
CH - Svizzera 3
DK - Danimarca 3
HR - Croazia 3
IL - Israele 3
KE - Kenya 3
KG - Kirghizistan 3
LV - Lettonia 3
MY - Malesia 3
TH - Thailandia 3
TW - Taiwan 3
AL - Albania 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
EU - Europa 2
GH - Ghana 2
GT - Guatemala 2
MK - Macedonia 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
EE - Estonia 1
GE - Georgia 1
HN - Honduras 1
IS - Islanda 1
JE - Jersey 1
LB - Libano 1
LK - Sri Lanka 1
Totale 8.851
Salva come PNG Salva come JPEG
Città #
Ashburn 466
Singapore 386
San Jose 277
Hong Kong 275
Santa Clara 253
Dallas 219
Chandler 149
Shanghai 144
Fairfield 92
New York 87
Boardman 83
Florence 81
Los Angeles 81
Abidjan 79
Sofia 78
London 74
Beijing 68
Munich 67
Ho Chi Minh City 66
Tokyo 62
Hanoi 52
Princeton 50
Helsinki 47
Atlanta 42
Pisa 42
Houston 41
Lauterbourg 39
Serra 39
Dakar 37
Wilmington 36
Istanbul 35
Lawrence 34
Milan 33
Turku 31
Woodbridge 30
Mumbai 29
Kent 28
Medford 28
Frankfurt am Main 25
Rome 25
Seattle 25
Lagos 23
Cambridge 21
Council Bluffs 21
Redwood City 21
San Francisco 21
Hyderabad 20
Rio de Janeiro 20
Buffalo 19
Massa 19
Ann Arbor 18
Hefei 18
Warsaw 18
Jakarta 17
Redondo Beach 17
São Paulo 17
Brooklyn 16
Denver 16
Bremen 15
Chennai 15
Chicago 15
Da Nang 15
Phoenix 14
San Diego 14
Washington 13
Amsterdam 12
Ogden 12
Fuzhou 11
Orem 11
Dong Ket 10
Memphis 10
Mexico City 10
Montreal 10
Tashkent 10
Bengaluru 9
Düsseldorf 9
Johannesburg 9
Nuremberg 9
Belo Horizonte 8
Curitiba 8
Livorno 8
Manchester 8
Marseille 8
Paris 8
Seoul 8
Amman 7
Baghdad 7
Haiphong 7
Madrid 7
Miami 7
Naples 7
Ottawa 7
Philadelphia 7
Roubaix 7
Turin 7
Vancouver 7
Vienna 7
Birmingham 6
Brasília 6
Brussels 6
Totale 4.548
Salva come PNG Salva come JPEG
Nome #
Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide (CGRP) Antagonists: a Disproportionality Analysis on VigiBase 841
Erratum to: Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System (Drug Safety, (2023), 46, 3, (283-295), 10.1007/s40264-022-01269-x) 292
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis 264
Disproportionality Analysis of ‘‘Early-Onset’’ Tardive Dyskinesia Stratified by Time to Onset Using FAERS Database. 257
Oral Presentation: Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase (R) Data and Evidence from Real World 230
The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis 225
Supporting the Spontaneous Reporting by Health Care Professionals of the University Hospital of Pisa, Italy: a Pilot Project from the Unit of Adverse Drug Reactions Monitoring 216
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence 200
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 198
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option 197
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study 179
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy 176
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 175
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 168
Fatal Fat Overload Syndrome Following Intravenous Lipid Emulsion Administration as Antidote in Suspected Anesthetic Intoxication: A Fatal Medication Error. 165
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases 161
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons 160
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports 158
Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis 156
The usefulness of listening social media for pharmacovigilance purposes: a systematic review 152
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs 152
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline 149
COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database 143
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy 142
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) 142
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies 140
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 138
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases 137
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact 135
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness? 135
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy 134
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study 134
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study 133
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study 131
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future 129
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy 128
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES 128
Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance 125
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients 123
Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study 122
Analysis of the Drug Related Emergency Department Admissions in Tuscany: The FARO Project 113
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease 113
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients 113
Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study 112
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments 112
Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis 111
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance 110
A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy 110
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy 101
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use 95
Communicating Drug Safety 91
Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO 87
Oral Presentation: Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study 80
Signals of Possibly Persistent Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Disproportionality Analysis Using the EudraVigilance Database 71
Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data 71
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall 67
Unresolved Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Signal Detection Analysis on Publicly Accessible Eudravigilance Data 59
null 56
Cases of acquired hemophilia A following COVID‐19 vaccines: Cogent safety signal or possible reporting/detection bias? Preliminary evidence from Tuscany, Italy 23
Totale 8.965
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.772
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.772
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022609 0 16 70 75 89 88 25 32 31 19 44 120
2022/2023818 110 156 57 45 65 68 27 32 179 1 75 3
2023/2024682 17 34 42 16 65 99 85 48 38 37 104 97
2024/20252.210 38 87 102 176 149 263 188 78 224 261 247 397
2025/20263.195 236 186 280 251 292 143 409 112 215 251 754 66
2026/20271.127 292 835 0 0 0 0 0 0 0 0 0 0
Totale 8.965